Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1975 2
1976 1
1978 2
1980 2
1982 1
1984 2
1985 5
1986 2
1987 5
1988 1
1989 5
1990 1
1991 3
1995 1
1998 3
2001 3
2002 3
2003 1
2004 1
2006 2
2007 3
2008 2
2009 2
2010 3
2011 3
2012 4
2013 9
2014 6
2015 5
2016 1
2017 1
2018 6
2019 6
2020 10
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

102 results
Results by year
Filters applied: . Clear all
Page 1
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG; proPSMA Study Group Collaborators. Hofman MS, et al. Among authors: francis rj. Lancet. 2020 Apr 11;395(10231):1208-1216. doi: 10.1016/S0140-6736(20)30314-7. Epub 2020 Mar 22. Lancet. 2020. PMID: 32209449 Clinical Trial.
TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).
Hofman MS, Emmett L, Violet J, Y Zhang A, Lawrence NJ, Stockler M, Francis RJ, Iravani A, Williams S, Azad A, Martin A, McJannett M; ANZUP TheraP team, Davis ID. Hofman MS, et al. Among authors: francis rj. BJU Int. 2019 Nov;124 Suppl 1:5-13. doi: 10.1111/bju.14876. Epub 2019 Oct 22. BJU Int. 2019. PMID: 31638341 Free article. Clinical Trial.
A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA, Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N. Hofman MS, et al. Among authors: francis rj. BJU Int. 2018 Nov;122(5):783-793. doi: 10.1111/bju.14374. Epub 2018 Jun 3. BJU Int. 2018. PMID: 29726071 Clinical Trial.
Human iPSC-Derived Neural Crest Stem Cells Exhibit Low Immunogenicity.
Mehler VJ, Burns CJ, Stauss H, Francis RJ, Moore ML. Mehler VJ, et al. Among authors: francis rj. Mol Ther Methods Clin Dev. 2020 Jan 13;16:161-171. doi: 10.1016/j.omtm.2019.12.015. eCollection 2020 Mar 13. Mol Ther Methods Clin Dev. 2020. PMID: 32055644 Free PMC article.
Mycobacterium mimicking metastatic melanoma.
Teh RW, Feeney K, Francis RJ, Phillips M, Millward MJ. Teh RW, et al. Among authors: francis rj. Intern Med J. 2013 Dec;43(12):1342-6. doi: 10.1111/imj.12209. Intern Med J. 2013. PMID: 24330366 Review.
102 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page